Combination treatment for advanced solid tumors with neuroendocrine markers
Part of Cancer clinical trials.
This study tests a combination of two medications (surufatinib and serplulimab) for advanced solid tumors that have stopped responding to standard treatment and show special neuroendocrine markers. The goal is to see if this combination can shrink tumors and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced cancer (lung, stomach, bowel, breast, or prostate) that has not responded to standard treatment, and your tumor shows special markers called neuroendocrine markers.
- You must be able to take care of yourself (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on a CT scan.
- You must be expected to live for at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (surufatinib, serplulimab, and standard chemotherapy) as a first treatment for advanced solid tumors that have neuroendocrine differentiation. The goal is to see if this combination helps control the cancer better than standard therapy alone.
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
This trial tests a combination of two oral and intravenous drugs – surufatinib and tislelizumab – for people with advanced lung cancer that shows certain hormone-like cell traits. The goal is to see if this pair can shrink or slow the cancer better than current treatments.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
This trial tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. If you have this diagnosis and haven't had prior systemic treatment, you may be eligible.
This trial tests whether adding three medicines—sintilimab, IBI310, and surufatinib—can control advanced, high-grade neuroendocrine tumors (that cannot be removed by surgery or have spread). It may help if your cancer has grown despite standard treatment, or if you cannot take standard treatment due to side effects.
Hear when a new Advanced Solid Tumors With Neuroendocrine Differentiation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.